Varian’s IntelliBlate Debuts in Europe 

Varian has released in Europe its next-generation microwave ablation solution for soft tissue tumor treatment, IntelliBlate.

Designed to provide clinicians with greater predictability, precision, and control, IntelliBlate is the cornerstone of a future-focused, integrated ecosystem for microwave ablation, according to Varian. The therapeutic device complements Siemens Healthineers’ suite of imaging and software solutions including: myAblation Guide for planning and post-procedural confirmation software, myNeedle Laser guidance system that enhances placement with a CT (computed tomography) scan, and ultrasound for assessment, placement, and monitoring during treatment. With the addition of IntelliBlate, the Varian and Siemens Healthineers’ offerings allow clinicians to plan, place, treat, monitor, and confirm ablation therapy in one environment, simplifying workflow and supporting greater confidence in targeting and treatment.

IntelliBlate delivers the versatility to meet patients’ unique clinical needs. It produces large, controlled spherical ablation zones for predictable treatment delivery. A novel feature, the Ximitry probe’s thermocouples, provide continuous temperature monitoring inside and outside the ablation zone, allowing clinicians to observe real-time temperature changes and make informed decisions.

The system provides two generators in one system making it compact and portable. The intuitive interface with fast set up and pre-programmed ablation zone settings makes the IntelliBlate a streamlined solution that helps reduce procedural barriers.

IntelliBlate was cleared by the U.S. Food and Drug Administration last year and enters the European market at a time of growing clinical evidence around thermal ablation. The COLLISION trial¹ demonstrated that thermal ablation can be as effective as the gold standard—surgical resection alone—in treating small-size colorectal liver metastases (CRLM) while resulting in significantly fewer complications, comparable overall survival, and shorter hospital stays for patients.

“The results of the COLLISION trial mark a milestone in how we think about ablation,” Varian President of Interventional Solutions Franck Facchini stated. “We have reached the point where the clinical evidence unrefutably supports the use of thermal ablation as a first-line treatment option, and not just an option for patients who cannot undergo surgery. IntelliBlate was designed to meet this shift in care, combining precision with intelligent software and imaging in a solution that fits seamlessly into modern cancer care workflows.”

IntelliBlate will be introduced to the European clinical community next month at CIRSE 2025; Varian and Siemens Healthineers will offer hands-on demonstrations and educational sessions to support training, best practice, and early clinical adoption. IntelliBlate represents a more targeted, less invasive approach to cancer care, offering new options to clinicians and new hope to patients.

Varian, a Siemens Healthineers company, has developed, built, and delivered technologies and solutions that help care providers worldwide treat patients. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, Varian is harnessing the power of perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway.

Reference
¹ van der Lei S, Puijk RS, Dijkstra M, et al. Thermal ablation versus surgical resection of small-size colorectal liver metastases (collision): An international, randomized, controlled, phase 3 non-inferiority trial. The Lancet Oncology 2025;26:187-199.